Our Company
THE LEADERS IN RNAi
Alnylam has pioneered RNA interference (RNAi)
Founded in 2002, Alnylam has advanced RNA interference (RNAi) to an innovative class of medicines with the belief that the RNAi approach to treating disease has the potential to help people around the world live longer, healthier, and more fulfilling lives.
Through groundbreaking research and relentless commitment to patients, Alnylam has cemented its position as an innovative and leading company in the field of RNAi. Now, we’re pioneering what’s next, working to bring the potential of RNAi to as many patients as possible around the world.
NOBEL PRIZE-WINNING SCIENCE
Our Science
Our Research
Our research currently focused on diseases with high unmet medical need, including transthyretin amyloidosis, rare diseases, cardiovascular diseases, metabolic diseases and neurological diseases. In addition, we are always following the science and continually searching for new disease targets that could benefit from our RNAi technology.
Transthyretin amyloidosis (ATTR)
Rare Diseases
Cardiovascular
Diseases
Metabolic Diseases
Neurologic
Diseases
Careers
JOIN OUR TEAM
As we pursue our goal of becoming a commercial organisation that can independently deliver medicines to patients, we’re seeking individuals with diverse skills, experiences, and backgrounds to help us build a world-class team. We’re based in Cambridge, USA, with hub sites in Zug, Switzerland, Amsterdam, Netherlands and Maidenhead, UK, but we’re also hiring throughout Europe.
Find our current job openings, here.